Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lyubov Moysik

Family Medicine Brooklyn, NY Doctor of Osteopathy

NPI 1053429167 CMS profile 47270

3000 Ocean Pkwy Ste L1, Brooklyn, NY 11235

Open in the dashboard

General payments

$9,347

455 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lyubov Moysik of Brooklyn, NY is reported in the CMS Open Payments database as having received $9,347 across 455 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $1,488 62
2022 General $2,090 95
2021 General $1,298 68
2020 General $2,044 110
2019 General $2,410 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lyubov Moysik
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Lyubov Moysik were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Lyubov Moysik Family Medicine median Middle half National median
2019 $2,410 $150 $41–$543 $163
2020 $2,044 $120 $32–$415 $114
2021 $1,298 $137 $35–$551 $132
2022 $2,090 $137 $37–$512 $149
2023 $1,488 $149 $42–$545 $160
2024 $17 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $1,069 39 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $924 42 payments
  3. GlaxoSmithKline, LLC. $857 35 payments
  4. Novartis Pharmaceuticals Corporation $792 48 payments
  5. Horizon Therapeutics plc $640 33 payments
  6. Merck Sharp & Dohme Corporation $611 27 payments
  7. AstraZeneca Pharmaceuticals LP $432 24 payments
  8. Scilex Pharmaceuticals Inc. $409 19 payments
  9. Lilly USA, LLC $364 22 payments
  10. Amarin Pharma Inc. $344 18 payments
  11. Other $2,907 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $9,347 455 payments
Products named General payments · program years 2019–2024
  1. XIFAXAN $857 38 payments
  2. ENTRESTO $710 43 payments
  3. CREON $472 21 payments
  4. RAYOS Rayos $448 23 payments
  5. RAYOS Rayos $448 23 payments
  6. RAYOS Rayos $448 23 payments
  7. VERQUVO $415 16 payments
  8. SPIRIVA RESPIMAT $342 18 payments
  9. TRELEGY ELLIPTA $335 15 payments
  10. LINZESS $325 21 payments
  11. Other $8,132 400 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

455 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record